Voyageur Pharmaceuticals Ltd
XTSX:VM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Voyageur Pharmaceuticals Ltd
Net Issuance of Common Stock
Voyageur Pharmaceuticals Ltd
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Voyageur Pharmaceuticals Ltd
XTSX:VM
|
Net Issuance of Common Stock
CA$3.3m
|
CAGR 3-Years
41%
|
CAGR 5-Years
85%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Net Issuance of Common Stock
$117.1m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
3%
|
CAGR 10-Years
83%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Net Issuance of Common Stock
-CA$6.4m
|
CAGR 3-Years
40%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Spectral Medical Inc
TSX:EDT
|
Net Issuance of Common Stock
CA$3.4m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-5%
|
|
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
Net Issuance of Common Stock
-$5.2m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-164%
|
CAGR 10-Years
N/A
|
|
Voyageur Pharmaceuticals Ltd
Glance View
Voyageur Pharmaceuticals Ltd. engages in exploring and development of barite, iodine, and fullerene Active Pharmaceutical Ingredient (API) minerals. The company is headquartered in Calgary, Alberta. The company went IPO on 2012-05-18. The firm is focused on the development of barite and iodine Active Pharmaceutical Ingredients (API) and imaging contrast agents for the medical radiology marketplace. The company owns a 100% interest in three barium sulfate (barite) projects. The firm operates through its subsidiaries, Voyageur Industrial Minerals Ltd. and Voyageur Minerals Inc. The company is focused on developing its barium sulfate project, Frances Creek, in BC, Canada for pharmaceutical barium contrast applications, such as x-radiation, computed tomography scans and magnetic resonance imaging applications. The company also owns mineral brine claims in Utah United States, including Frances Creek, Jubilee Mountain and Pedley Mountain.
See Also
What is Voyageur Pharmaceuticals Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
3.3m
CAD
Based on the financial report for Nov 30, 2025, Voyageur Pharmaceuticals Ltd's Net Issuance of Common Stock amounts to 3.3m CAD.
What is Voyageur Pharmaceuticals Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
85%
Over the last year, the Net Issuance of Common Stock growth was 578%. The average annual Net Issuance of Common Stock growth rates for Voyageur Pharmaceuticals Ltd have been 41% over the past three years , 85% over the past five years .
